Merck & Co.
AWARDS
NEWS
“Over the past few years there has been a good amount of information presented at ADA. This year though, with all of the data presented, this was the most exciting year,” Todd Hobbs, U.S. chief medical officer of Novo Nordisk, told BioSpace in an exclusive interview.
The approval was built on data from the Phase III KEYNOTE-048 clinical trial.
Under the terms of the deal, a Merck subsidiary is buying all outstanding shares of Tilos for a total of up to $773 million, including an upfront payment and various potential milestone payments.
With more than 16,000 attendees from 67 countries and hundreds, even thousands of presentations, it can be difficult to get a real grip on everything that went on at the 2019 BIO International Convention held in Philadelphia. Here’s a look at just a few of the highlights.
ASCO called rare cancer treatments the “advance of the year” in oncology.
Patients were given Merck’s Keytruda (pembrolizumab) in combination with platinum chemotherapy, Keytruda by itself or chemotherapy by itself. The trial results found that the combination extended survival, and immunotherapy alone also worked well for some patients.
JOBS
IN THE PRESS